Vivos Inc. Submits Early Feasibility IDE Application for RadioGel® to FDA
Vivos Inc. has submitted an Early Feasibility Investigational Device Exemption (IDE) application to the FDA for its RadioGel® Precision Radionuclide Therapy™, which targets solid tumors while minimizing radiation exposure to healthy tissue. This submission signifies a major milestone in its regulatory pathway and aims to advance RadioGel® into human clinical trials. The application is based on extensive technical data and clinical insights from ongoing trials, and the company expects FDA feedback within 30 days.
Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy™ (PRnT) with its innovative RadioGel® technology, today announced the submission of its Early Feasibility IDE application to the FDA. This milestone represents a significant advancement in the Company’s regulatory pathway and builds directly on the substantial progress detailed in its February 10, 2026 update.
